[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100395586":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":20,"locations":29,"responsibleParty":48,"collaborators":10,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":70,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"National Institutes of Health Clinical Center (CC)","NIH",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Cancer patients",null,"Individuals with history of cancer and detected or suspected germline mutation in BAP1 TPDS",{"label":13,"type":10,"description":14,"interventionNames":10},"Relatives of cancer patients","First- or second-degree relatives of a cancer patient (with or without cancer) with documented BAP1 tumor predisposition syndrome (TPDS)",[16],{"name":17,"affiliation":18,"role":19},"David S Schrump, M.D.","National Cancer Institute (NCI)","PRINCIPAL_INVESTIGATOR",[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Rebecca B Alexander","CONTACT","(240) 781-4037","rebecca.alexander@nih.gov",{"name":17,"role":23,"phone":27,"phoneExt":10,"email":28},"(240) 760-6239","david_schrump@nih.gov",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"National Institutes of Health Clinical Center","RECRUITING","Bethesda","Maryland","20892","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-77.10026,38.98067,{"lat":42,"lon":41},[45],{"name":46,"role":23,"phone":47,"phoneExt":10,"email":10},"For more information at the NIH Clinical Center contact National Cancer Institute Referral Office","888-624-1937",{"type":49,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100395586","prospective-evaluation-of-high-resolution-dual-energy-computed-tomographic-imaging-noninvasive-liquid-biopsies-and-minimally-invasive-surgical-surveillance-for-early-detection-of-mesotheliomas-in-patients-with-bap1-tumor-predisposition-syndrome-100395586",false,"NCT04431024","Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome","* ELIGIBILITY CRITERIA:\n\nInclusion Criteria for Genetic Testing\n\n-Eligible participants include:\n\n--Individuals with a history of any malignancy with known or suspected germline mutations involving BAP1\n\nOR\n\n--First- or second-degree relatives of patients (with or without cancer) with documented BAP1 tumor predisposition syndrome (TPDS)\n\n* Age \\>= 30 years.\n* All participants must understand and be willing to sign a written informed consent document.\n\nInclusion Criteria for Surveillance\n\n* Eligible participants include those who completed step 1 genetic testing with study-confirmed BAP1 or other germline TPDS mutation.\n* Completed co-enrollment on protocol 06C0014, \"Prospective Evaluation of Genetic and Epigenetic Alterations in Patients with Thoracic Malignancies.\"",true,"ALL","30 Years","120 Years",{"count":61,"type":62},300,"ESTIMATED","OBSERVATIONAL","Background:\n\nA germline mutation is a change to a person s genes that is carried through their DNA. These mutations can be passed on from parents to their offspring. Germline mutations in a gene called BAP1 are linked to the development of mesothelioma and other cancers. Researchers want to follow people with these mutations to learn more.\n\nObjective:\n\nTo see if researchers can improve how people who have or are suspected to have a BAP1 mutation are monitored over time.\n\nEligibility:\n\nPeople age 30 and older who are suspected to have a BAP1 germline mutation.\n\nDesign:\n\nParticipants will be screened with a personal and family medical history. Their medical records may be reviewed. They will give a blood or saliva sample to test for a BAP1 mutation. They will get genetic counseling.\n\nTo take part in this study, participants will enroll on 2 to 3 other protocols.\n\nParticipants will have a physical exam. They may have a tumor biopsy. They will give blood and urine samples. They will have skin and eye exams.\n\nSome participants will have video-assisted thoracoscopy to examine the chest and lungs and diagnose suspicious areas. For this, a small camera is inserted into the chest through a small incision.\n\nSome participants will have laparoscopy to examine the organs inside the abdomen. For this, a small camera is inserted into the abdomen through a small incision.\n\nParticipants will have imaging scans of the chest, abdomen, and pelvis. They may have brain scans.\n\nParticipants will visit the NIH once a year for follow-up exams.\n\nParticipation lasts indefinitely.",[66,67,68,69],"Familial Cancer","BRCA1-Associated Protein-1 (BAP1) Mutations","Tumor Predisposition Syndrome (TPDS)","Mesothelioma",[71,72,73,74,75,76],"Germline Mutation in the BAP1 Gene","BRCA1-Associated Protein-1","Genetics","Familial Background","Natural History","DECT","2026-06-27",{"date":79,"type":80},"2026-06-30","ACTUAL",{"date":82,"type":80},"2021-03-30",{"date":84,"type":62},"2038-06-30",{"name":18,"class":6},1]